Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
On CNBC's "Mad Money Lightning Round," Jim Cramer said TORM plc (NASDAQ:TRMD) has a "remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down."
Jim Cramer表示，在CNBC的“疯狂金钱闪电回合”节目中，TORm plc (NASDAQ: TRMD) 的“股息收益率非常高。只要有这个股息收益率，股票就会保持上涨。但是，当事情开始变坏时，在这个业务中他们总是会这样做，这种收益率就会开始下降。”
On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48.
7月23日，Evercore ISI Group 分析师Jonathan Chappell 维持对TORm的推荐评级，将股价目标上调至48美元，而之前为45美元。
Cramer recommended buying Trane Technologies plc (NYSE:TT). "Hard to stop a Trane," he added.
Cramer 建议购买 Trane Technologies plc (NYSE: TT)。他补充说，“很难阻止“Trane”发展。”
Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earnings at $3.08 per share, up from $2.68 per share in the year-ago period. Trane is projected to post quarterly revenue of $5.13 billion compared to $4.7 billion a year ago, according to data from Benzinga Pro.
Trane Technologies将于7月31日星期三公布其第二季度财报。根据Benzinga Pro的数据，分析师预计该公司报告的季度每股收益为3.08美元，高于去年同期的2.68美元。预计Trane将发布营业收入51.3亿，而去年同期为47亿。
When asked about Axsome Therapeutics, Inc. (NASDAQ:AXSM), he said, "This is central nervous system, CNS. If you can make a breakthrough in CNS, your stock will double. If not, it will just go down. That's a double or nothing stock right there."
当被问及Axsome Therapeutics, Inc. (NASDAQ: AXSM) 时，他说：“这是中枢神经系统，CNS。如果在CNS方面取得突破，你的股票会翻倍。否则，它就会下跌。那是一个赌一赔二的股票。”
On July 22, Needham analyst Ami Fadia initiated coverage on Axsome Therapeutics with a Buy rating and announced a price target of $130.
7月22日，Needham分析师Ami Fadia发起对Axsome Therapeutics的覆盖，评级为买入，并宣布130美元的目标价。
The "Mad Money" host said SAP SE (NYSE:SAP) is "incredible" and recommended buying the stock. "I think that SAP is not done going higher," he added.
该“疯狂金钱”主持人说，SAP SE（纽约证交所：SAP）“令人难以置信”，并建议购买该股票。他补充说，“我认为SAP还没有涨完。”
On July 22, SAP reported second-quarter earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro.
7月22日，SAP报告了每股收益为82美分的第二季度财报，低于分析师共识预估的每股收益1.19美元。根据Benzinga Pro的数据，季度销售额为892亿美元，低于分析师共识预估的896亿美元，同比增长8.81%。
Price Action:
价格行动：
- Torm shares gained 2% to settle at $40.45 on Tuesday.
- Trane shares rose 2.3% to settle at $344.96.
- Sap rose 7.1% to close at $214.76 during Tuesday's session.
- Axsome Therapeutics shares fell 0.5% to settle at $85.66 on Tuesday.
- Torm股价上涨2％，收于40.45美元。
- Trane股价上涨2.3％，收于344.96美元。
- SAP股价上涨7.1％，收于214.76美元。
- Axsome Therapeutics股价下跌0.5％，收于85.66美元。
- Best Buy, Kroger And 2 Other Stocks Insiders Are Selling
- 百思买、Kroger和其他2只股票的内部人士正在出售